AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Healthcare
Clarity Pharmaceuticals (ASX:CU6) Launches New Cancer Radiopharmaceutical
December 18, 2024 11:30 AM AEDT| By Team Kalkine MediaHighlights,Clarity Pharmaceuticals (CU6) advances a new radiopharmaceutical, SAR-,bisFAP,The product targets multiple cancers with diagnostic and treatment potential,SAR-,bisFAP,demonstrated improved retention and uptake in preclinical trials,Clarity...
Ramsay Health Care (ASX:RHC) Faces Five-Year Decline in Share Price and Earnings
December 18, 2024 11:12 AM AEDT| By Team Kalkine MediaHighlights,Ramsay Health Care (RHC) faces long-term stock decline,.,Earnings per share (EPS) fell annually over the last five years,.,Total shareholder returns were supported by dividends,.,Ramsay Health Care (ASX:RHC), a leading player in the health...
Actinogen Medical (ASX:ACW) Faces Challenges Despite Strong Revenue Growth
December 17, 2024 06:54 PM AEDT| By Team Kalkine MediaHighlights,Actinogen Medical (ACW) shares experienced significant volatility over the past three years.,Revenue growth has been substantial but share price performance remains under pressure.,Insider buying in the last three months signals confidence...
Prescient Therapeutics Appoints Global Pharmaceutical Leader as New CEO
December 17, 2024 01:42 PM AEDT| By Team Kalkine MediaHighlights,Prescient Therapeutics (PTX) names James McDonnell as its new CEO,McDonnell has extensive experience in global oncology and pharmaceutical sectors,The appointment is effective from January 20, 2025,Prescient Therapeutics (ASX:PTX), a clini...
Immutep Reports Positive Safety Data for Flagship Drug IMP761, Shares Slip 3%
December 17, 2024 12:26 PM AEDT| By Team Kalkine MediaHighlights,Immutep tested IMP761, a LAG-3 agonist, in a conceptual safety study involving 49 healthy participants.,No adverse effects were reported, confirming the safety of the world’s first LAG-3 agonist antibody in its early testing phase.,The stu...
Race Oncology (ASX:RAC) Advances Cancer Research with R&D Rebate
December 17, 2024 12:01 PM AEDT| By Team Kalkine MediaHighlights,Race Oncology secures over A$5 million R&D rebate to advance lead drug,bisantrene,Funding boosts R&D for both domestic and international projects,Key focus on addressing unmet needs in oncology treatments,Race Oncology (ASX:RAC) has receiv...
Anteris Technologies Now Trading on Nasdaq and ASX Following Re-domiciliation
December 17, 2024 11:36 AM AEDT| By Team Kalkine MediaHighlights,Anteris,completes re-domiciliation to the US and begins trading on Nasdaq,.,Shares of,Anteris,Technologies listed under (AVR) on the ASX and Nasdaq,.,IPO funds will accelerate heart valve product development and clinical trials,.,Anteris T...
Control Bionics Targets Strong US Revenue Growth and Expands Market Reach
December 17, 2024 10:58 AM AEDT| By Team Kalkine MediaHighlights,Control Bionics (CBL) expects strong revenue growth for the US market in FY25,.,Operational initiatives and cost reductions drive improved efficiency,.,Growing demand for Drove module strengthens market presence,.,Control Bionics (ASX:CBL)...
ECS Botanics Reports Record Cannabis Yields with Enhanced Enclosures
December 16, 2024 03:45 PM AEDT| By Team Kalkine MediaHighlights,ECS Botanics (ECS) achieves a 50% increase in cannabis flower yields through innovative enclosure designs.,Enhanced enclosures deliver improved flower quality and higher-grade cannabis buds.,New infrastructure positions the company for inc...
Orthocell (ASX:OCC) Marks Key Milestone with First Sales of Remplir™ in Singapore
December 16, 2024 01:44 PM AEDT| By Team Kalkine MediaHighlights,Orthocell,(OCC) achieves initial sales of,Remplir,™ in Singapore,.,Expansion into Singapore positions the product in the ASEAN region's nerve repair market,.,Regulatory filings for US FDA clearance set to accelerate growth globally,.,Ortho...
Control Bionics Expands NeuroStrip Technology into US and Japanese Markets
December 16, 2024 12:48 PM AEDT| By Team Kalkine MediaHighlights,Control Bionics (CBL) enters US sports and Japanese rehabilitation sectors with,NeuroStrip,agreements,.,Strategic partnerships target enhanced athletic performance and neurological recovery,.,New deals expected to generate revenue through...
INOVIQ's Early-Stage Success in Targeting Breast Cancer with Exosomes
December 16, 2024 12:18 PM AEDT| By Team Kalkine MediaHighlight:,INOVIQ Ltd (,ASX:IIQ,) reports initial success in using exosomes from natural killer (NK) cells to target and kill breast cancer cells in vitro.,Exosomes,,proteins,and DNA carrying nanoparticles, are engineered with chimeric antigen recept...
Invex Reports Promising Results in Alzheimer’s Simulation Using Exenatide
December 16, 2024 12:11 PM AEDT| By Team Kalkine MediaHighlights,Exenatide's Role in Alzheimer's Simulation,:,Invex,Therapeutics has successfully tested exenatide, a diabetes drug, in a 3D human brain model to assess its potential in delaying Alzheimer’s disease (AD). This marks the first demonstration...
Acrux Secures Fourth FDA Approval for Nitroglycerin Ointment, Advancing U.S. Commercialisation
December 13, 2024 03:15 PM AEDT| By Team Kalkine MediaHighlights:,FDA Approval and Commercialisation:,Acrux Ltd (ASX: ACR) receives FDA approval for,Nitroglycerin,Ointment 0.4%, a topical treatment for chronic anal fissures, enabling U.S. commercialisation through licensee,TruPharma,.,Market Potential:,...
Nova Eye Medical (ASX:EYE) Positioned for a Profitable Turnaround
December 13, 2024 12:38 PM AEDT| By Team Kalkine MediaHighlights,Nova Eye Medical (EYE) is targeting profitability within a short timeframe,.,Analysts predict significant growth for the glaucoma treatment innovator,.,The company,operates,debt-free, reducing financial risk,.,Nova Eye Medical (ASX:EYE), a...
Breakthrough in Head and Neck Cancer Treatment by Immutep
December 12, 2024 03:27 PM AEDT| By Team Kalkine MediaHighlights,Immutep (IMM) shares data from its Phase IIb TACTI-003 trial.,Promising results in treating head and neck squamous cell carcinoma (HNSCC).,Combination therapy shows significant improvement in survival rates.,Immutep (ASX:IMM) has revealed...
Orthocell (ASX:OCC) Achieves Early Sales of Nerve Repair Product in Singapore
December 12, 2024 03:20 PM AEDT| By Team Kalkine MediaHighlights,Orthocell,(OCC) marks its first sales of,Remplir,in Singapore,.,Remplir,supports nerve healing with its collagen-based design,.,Early success achieved ahead of its,anticipated,2025 launch,.,Orthocell (ASX:OCC), a leading regenerative medic...
Immutep Ltd (ASX: IMM) Soars on Positive Clinical Trial Results, Shares Up 6%
December 12, 2024 01:42 PM AEDT| By Team Kalkine MediaHighlights,Immutep Ltd sees a sharp rise in share price after announcing promising results from TACTI-003 Phase IIb trial.,The trial’s positive outcomes for head and neck cancer treatment fuel investor optimism.,CEO Marc Voigt highlights the potentia...
LTR Pharma Launches Online Men's Health Platform
December 12, 2024 12:52 PM AEDT| By Team Kalkine MediaHighlights:,Launch of SPONTAN,:,LTR Pharma (,ASX:LTP,) has introduced an online men’s health platform to,facilitate,the regulated prescription of its nasal spray Viagra product, SPONTAN.,Market Response,:,Despite,initial,enthusiasm, the company's sha...
Orthocell Ltd (ASX:OCC) Makes Breakthrough with First Remplir™ Sales in Singapore
December 12, 2024 12:05 PM AEDT| By Team Kalkine MediaHighlights,Orthocell,Ltd (OCC) achieves first sales of,Remplir,™ in Singapore.,Remplir,™ is now sold in Singapore, Australia, and New Zealand.,Sales and surgeon endorsements of,Remplir,™ are growing.,Orthocell Ltd (ASX:OCC), a leader in regenerative...
Advertise your brand on Kalkine Media